At the ESC 2024 Congress (30 August-2 September, London, UK, and online), leading lipid specialists discussed recent evidence about the contribution of elevated triglycerides to risk of atherosclerotic cardiovascular disease, and reported latest data from clinical trials of TG-lowering medicines, including progress with novel agents that reduce atherogenic lipoproteins by targeting either apoC3 or ANGPTL3.
Read the reports:
- Targeting TG – is it worth it?
- PALISADE trial: plozasiran reduces TG and pancreatitis in persistent chylomicronaemia
- Targeting triglycerides after ACS
- Smooth transition from volanesorsen to olezarsen in FCS
- TRL reduction with retatrutide in T2D linked to fall in ANGPTL3/8
Reports by Jenny Bryan
